AI-Powered Data Analytics and Multi-Omics Integration for Next-Generation Precision Oncology and Anticancer Drug Development
Article Sidebar
Main Article Content
Abstract
The recent rapid evolution of artificial intelligence (AI), big data analytics, and multi-omics technologies is changing modern precision oncology. These tools have opened up new opportunities to understand the heterogeneity of the tumor, drug response, and biomarker discovery. Traditional cancer therapies often fail because we do not fully understand the genomic, transcriptomic, proteomic, and metabolomic differences that are present between patients and within tumor microenvironments. Recent progress in computational intelligence, integrative omics pipelines, and drug discovery through machine learning holds significant potential to enable the personalization of cancer treatment, identify new anticancer compounds, and accelerate the development of new therapeutics. This study provides a detailed analysis of how AI-enabled data analytics and the integration of multi-omics capabilities are transforming next-generation precision oncology and the development of anticancer drugs. It synthesizes the insights from the recent studies such as big data facilitated plant biotechnology for bioactive anticancer compounds (Ahmed et al., 2023), machine learning enabled genomic selection framework (Saimon et al., 2023), artificial intelligence based on ischemic stroke biomarker discovery (Manik, 2023), cervical cancer prediction (Manik, 2022), predictive multi-omics system of neurodegenerative disease (Manik, 2021), and chronic disease analytics (Manik et al., 2021) to describe the potential of innovative computational frameworks to overcome existing Generative AI, deep learning, hybrid ML, and systems biology stand out as pillars on precision drug discovery, immuno-oncology improvement, high throughput compound selection, and early diagnosis of various cancers. The paper then develops a conceptual AI-driven multi-omics architecture for real-world oncology applications. It demonstrates how the genomic layer, transcript sequencing layer, epigenomic layer, proteome, microbiomics, and metabolomics layers can be harmonized using machine learning, federated learning, Bayesian optimization, and network-based models. By addressing literature from both modern times and fundamentals, this work uncovers gaps in the current oncology pipelines, suggests new strategies in AI for real-world translation into clinical oncology, and thereby establishes the potential of bioinformatics-driven solutions in anticancer drug development. The results highlight the importance of interdisciplinary research and data science approaches in providing equitable, individualized, and high-precision cancer care.
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
References
WHO, “Cancer,” World Health Organization, 2025. https://www.who.int/news-room/fact-sheets/detail/cancer
I. Dagogo-Jack and A. T. Shaw, “Tumour heterogeneity and resistance to cancer therapies,” Nat. Rev. Clin. Oncol., vol. 15, no. 2, pp. 81–94, 2018, doi: https://doi.org/10.1056/NEJMra1406189.
M. M. T. G. Manik, “Multi-Omics Integration with Machine Learning for Early Detection of Ischemic Stroke Through Biomarkers Discovery,” J. Ecohumanism, vol. 2, no. 2, pp. 175 –187, 2023, doi: https://doi.org/10.62754/joe.v2i2.6800.
M. M. T. G. Manik et al., “Leveraging Ai-Powered Predictive Analytics for Early Detection of Chronic Diseases: A Data-Driven Approach to Personalized Medicine,” Nanotechnol. Perceptions, vol. 17, no. 3, pp. 269–288, 2021, doi: https://doi.org/10.62441/nano-ntp.v17i3.5444.
M. A. Miah, E. Rozario, F. B. Khair, M. K. Ahmed, M. M. R. Bhuiyan, and M. M. T. G. Manik, “Harnessing Wearable Health Data and Deep Learning Algorithms for Real-Time Cardiovascular Disease Monitoring and Prevention,” Nanotechnol. Perceptions, vol. 15, no. 3, pp. 326–349, 2019, doi: https://doi.org/10.62441/nano-ntp.v15i3.5278.
M. M. T. G. Manik, “An Analysis of Cervical Cancer using the Application of AI and Machine Learning,” J. Med. Heal. Stud., vol. 3, no. 2, pp. 67–76, 2022, doi: https://doi.org/10.32996/jmhs.2022.3.2.11.
M. Manik, M. M. Rahman, M. M. Bhuiyan, M. S. Islam, S. Hossain, and S. Hossain, “The future of drug discovery utilizing generative AI and big data analytics for accelerating pharmaceutical innovations,” Nanotechnol. Perceptions, vol. 14, no. 3, pp. 120–135, 2018.
K. A. MD et al., “Big Data in Plant Biotechnology: Leveraging Bioinformatics to Discover Novel Anticancer Agents from Flora,” J. Med. Heal. Stud. Учредители Al-Kindi Cent. Res. Dev., vol. 4, no. 6, pp. 126–133, 2023.
M. M. T. G. Manik et al., “Integrating Genomic Data and Machine Learning to Advance Precision Oncology and Targeted Cancer Therapies,” Nanotechnol. Perceptions, vol. 18, no. 2, pp. 219–243, 2022, doi: https://doi.org/10.62441/nano-ntp.v18i2.5443.
M. M. T. G. Manik, “Multi-Omics System Based on Predictive Analysis with AI-Driven Models for Parkinson’s Disease (PD) Neurosurgery,” J. Med. Heal. Stud., vol. 2, no. 1, pp. 42–52, 2021, doi: https://doi.org/10.32996/jmhs.2021.2.1.5.
M. M. T. G. Manik, “Biotech-Driven Innovation in Drug Discovery: Strategic Models for Competitive Advantage in the Global Pharmaceutical Market,” J. Comput. Anal. Appl., vol. 28, no. 6, pp. 41–47, 2020, [Online]. Available: https://eudoxuspress.com/index.php/pub/article/view/2874
D. C. Cireşan, A. Giusti, L. M. Gambardella, and J. Schmidhuber, “Mitosis detection in breast cancer histology images with deep neural networks,” in International conference on medical image computing and computer-assisted intervention, 2013, pp. 411–418. doi: https://doi.org/10.1007/978-3-642-40763-5_51.
B. H. Menze et al., “The multimodal brain tumor image segmentation benchmark (BRATS),” IEEE Trans. Med. Imaging, vol. 34, no. 10, pp. 1993–2024, 2014, doi: https://doi.org/10.1109/TMI.2014.2377694.
H. J. W. L. Aerts et al., “Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach,” Nat. Commun., vol. 5, no. 1, p. 4006, 2014, doi: https://doi.org/10.1038/ncomms5006.
A. Esteva et al., “Dermatologist-level classification of skin cancer with deep neural networks,” Nature, vol. 542, no. 7639, pp. 115–118, 2017, doi: https://doi.org/10.1038/nature21056.
B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz Jr, and K. W. Kinzler, “Cancer genome landscapes,” Science (80-. )., vol. 339, no. 6127, pp. 1546–1558, 2013, doi: https://doi.org/10.1126/science.1235122.
R. Poplin et al., “A universal SNP and small-indel variant caller using deep neural networks,” Nat. Biotechnol., vol. 36, no. 10, pp. 983–987, 2018, doi: https://doi.org/10.1038/nbt.4235.
G. P. Way et al., “Machine learning detects pan-cancer ras pathway activation in the cancer genome atlas,” Cell Rep., vol. 23, no. 1, pp. 172–180, 2018, doi: https://doi.org/10.1016/j.celrep.2018.03.046.
D. J. Newman and G. M. Cragg, “Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019,” J. Nat. Prod., vol. 83, no. 3, pp. 770–803, 2020, doi: https://doi.org/10.1021/acs.jnatprod.9b01285.
J. D. Cohen et al., “Detection and localization of surgically resectable cancers with a multi-analyte blood test,” Science (80-. )., vol. 359, no. 6378, pp. 926–930, 2018, doi: https://doi.org/10.1126/science.aar3247.
M. C. Liu et al., “Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA,” Ann. Oncol., vol. 31, no. 6, pp. 745–759, 2020, doi: https://doi.org/10.1038/s41586-020-2090-1.
M. M. T. G. Manik et al., “The Role of Big Data in Combatting Antibiotic Resistance Predictive Models for Global Surveillance,” Nanotechnol. Perceptions, vol. 16, no. 3, pp. 361–378, 2020, doi: https://doi.org/10.62441/nano-ntp.v16i3.5445.